Lane Michael sold $2.7M of IDXX

Lane Michael (Executive Vice President) sold 3,979 shares of IDEXX LABORATORIES INC /DE (IDXX) at an average of $688.64 ($687.46–$689.70, $2.74M total) across 3 trades on 2026-11-04.

Original reporting
SEC EDGAR · Lane Michael
Published Nov 5, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The disclosed sale adds a fresh data point on insider holdings, potentially influencing short‑term price action.

02

Market read

A C‑suite insider sale of $2.7 M is a modest but noteworthy event for IDXX shareholders.

03

What to watch

Michael's remaining stake is still sizable; the sale represents less than 0.1% of float.

Relevance 6/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filings disclose insider transactions; traders monitor them for clues about management sentiment.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

Executive Vice President Lane Michael sold 3,979 shares for $2.74 M, reducing his stake to 4,076 shares.

Expected impact

likely modest downside as the market prices the insider sell.

Evidence & confidence

A C‑suite insider sold a multi‑million‑dollar position; such sales often trigger short‑term selling pressure.

Market effects

Minimal impact on the broader diagnostics sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Lane Michael

    Executive Vice President of IDEXX Laboratories who sold shares.

  • IDEXX Laboratories Inc.

    US‑listed diagnostics company (ticker IDXX).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.